this is probably pointless wishful thinking, but seems to me Sanofi would now represent the most logical partnering candidate, given petrylak's analysis of the provenge followed by taxotere subgroup in 9901/9902A.
DNDN would no doubt be negotiating from a position of weakness (before even factoring in Gold's "wild card" status into the equation), but i think a win-win deal could possibly be structured, though my personal opinion is that Gold (& his youthful inexperience & ego & major gaffs) is the major stumbling block.
assuming that there is a very good chance that 9902B interim or final results are stat sig within the next 2 to 3 years, Sanofi could essentially take a "right of first refusal" option on the company by making a 19% equity investment or about 15M shares (keeping it below 20% to avoid arcane accounting rules of presumed 'significant influence', while still scaring off any other potential suitors) for say $7.50 a share, plus a reduced royalty on worldwide Provenge sales.
the company raises $100M in cash, enough to keep their R&D development alive & hopefully progressing the next indication for active cellular immunotherapy, while waiting for 9902B results to mature...but more importantly imo, it eliminates lingering uncertainty about their intermediate future and establishes greater credibility & thereby a floor to support the share price.
that said, i suspect gold, having "endured" two discounted dilutions to get to this point, will opt to continue that route to retain control of Provenge, since he, as CEO, can virtually personally remedy any diultion he might suffer, and has already demonstrated little regard for diluting DNDN shareholders...
jmo
AI
